French
Arabic
Hematology-Oncology
The leading role of Hôtel-Dieu de France in the treatment of cancer patients dates back to 1925, when the "Institute of Radiology and Cancer Treatment" was founded. This mission to fight cancer has been ongoing throughout the years on a national and regional scale. The Department of Hematology-Oncology treats almost 20% of the Lebanese oncology patients annually.
It includes a conventional hospitalization department and a day hospital.
The day hospital (HDJ) is meant for admitting oncology patients for a period not exceeding 8 hours. The HDJ is intended to receive about 40 patients daily.
The Department of Hematology-Oncology works in close collaboration with several departments in the hospital. Multidisciplinary team meetings are held on a monthly basis.
The Department was the first Arab cancer center accredited by ESMO as an "ESMO Designated Center of Integrated Oncology and Palliative Care" in September 2015, and the accreditation was renewed in September 2018.
The Department, in its academic mission, ensures the training of residents in hematology-oncology.
In addition to its long-standing academic mission, the deep expertise of its doctors and nursing staff in the personalized and humanized care provided for patients, the Department of Hematology-Oncology has also been able to achieve several goals, including:
- Integral participation in international clinical trials of new therapeutic modalities. Pharmaceutical companies and global health organizations consider this Department as a qualified regional research hub to launch their therapeutic trials. The patients of the Department can thus benefit from innovative medicines at an early stage, while respecting medical ethics.
- Publication of the Department's clinical studies and research as scientific articles. This Department ranks first at the institutional level, and even at the national level, in the number of publications it issues, with approximately 40 articles published annually in international journals. These publications are discussed and presented at a forum called the Oncology Research Forum, which is held annually in mid-September.
